Majima M, Katori M
Department of Pharmacology, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
Trends Pharmacol Sci. 1995 Jul;16(7):239-46. doi: 10.1016/s0165-6147(00)89033-1.
The renal kallikrein-kinin system has been shown to be important in the development of hypertension, but its precise role remains to be determined. The recent use of mutant rats that are deficient in plasma kininogens and hence incapable of generating kinin in the renal tubules has facilitated elucidation of the involvement of kinin in hypertension. In this article, Masataka Majima and Makoto Katori provide evidence that the renal kallikrein-kinin system plays a crucial role in the development of hypertension and discuss a novel rationale for developing effective new antihypertensive drugs.
肾激肽释放酶-激肽系统已被证明在高血压的发生发展中起重要作用，但其确切作用仍有待确定。最近使用血浆激肽原缺乏因而无法在肾小管中产生激肽的突变大鼠，有助于阐明激肽在高血压中的作用。在本文中，真岛正孝和片取诚提供了证据，证明肾激肽释放酶-激肽系统在高血压的发生发展中起关键作用，并讨论了开发有效的新型抗高血压药物的新理论依据。
